For systemic comparison, the staining intensity of anti-PRSS23 in 56 Taiwan breast cancer samples was classified as strong (Fig. S2A), moderate (Fig. S2B), or weak (Fig. S2C). Here, PRSS23 is linked to breast carcinoma.